Printed as of 7/17/2025



Disclosures

Personal Commercial (18)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
AstraZeneca Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Axon	Research/Research Grants	Significant (>= \$5,000)	
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	
BridgeBio Pharmacy	Consultant Fees/Honoraria	Significant (>= \$5,000)	
Corvia	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
DoD	Research/Research Grants	Significant (>= \$5,000)	
Edwards	Consultant Fees/Honoraria	Significant (>= \$5,000)	
Eli Lilly and Company	Consultant Fees/Honoraria	Significant (>= \$5,000)	
Janssen Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	
Medtronic	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Merck & Co., Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	
NGMBio	Consultant Fees/Honoraria	Significant (>= \$5,000)	
NIH/NHLBI	Research/Research Grants	Significant (>= \$5,000)	
Novo Nordisk Inc.	Research/Research Grants	Significant (>= \$5,000)	
Rivus	Research/Research Grants	Significant (>= \$5,000)	
ShouTi	Consultant Fees/Honoraria	Significant (>= \$5,000)	
Tenax	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
VADovations	Consultant Fees/Honoraria	None (\$0)	

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 3/7/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 3/7/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 3/7/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.